Onxeo Poster Demonstrating Unique Livatag® Mechanism of Action Accepted for Presentation at AACR Annual Meeting

Paris (France), Copenhagen (Denmark) – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology therapeutics, today announced that a poster demonstrating the unique mechanism of action of Livatag® has been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, one of the most prestigious meetings on preclinical research in the field of oncology, being held April 16-20, 2016 in New Orleans, LA, USA.

Preclinical studies were conducted in relevant models to evaluate the mechanism of action of doxorubicin loaded nanoparticle formulation (Livatag®) in comparison with free doxorubicin in overcoming hepatocellular carcinoma (HCC) cellular resistance.

The complete data, and their implication on the role of nanoparticles in the treatment of HCC will be discussed at AACR during the poster session by Dr. Graham Dixon, PhD, Chief Scientific Officer at Onxeo.

Livatag®’s nanoformulation is designed to accumulate doxorubicin in the liver and evade tumor cell resistance mediated by multiple drug resistance (MDR) efflux pumps. The efficacy of Livatag® is currently being evaluated in a Phase 3 trial (ReLive study) compared to Best Standard of Care (BSC) in patients with advanced HCC.

Logistical details of the poster are as follows:

Abstract #2143 / Poster #13: Mechanistic study of the relative cytotoxicity of doxorubicin loaded nanoparticle formulation compared to free doxorubicin in hepatocellular carcinoma (HCC) cell lines

Date:                     Monday, April 18, 2016

Time:                     1:00 – 5:00 p.m. EDT

Location:              Section 18